PPN News Staff
The FDA has approved betrixaban (Bevyxxa, Portola Pharmaceuticals) for the prophylaxis of venous thromboembolism (VTE) in adult patients hospitalized for an acute medical illness who are at risk for thromboembolic complications due to moderate or severe restricted mobility and other risk factors for VTE.
Betrixaban is an oral, once-daily factor Xa inhibitor. Its approval was based on data from the Phase III multinational APEX trial comparing extended-duration betrixaban (35-42